Endogenous complement human serum bactericidal assay (enc-hSBA) for vaccine effectiveness assessments against meningococcal serogroup B

Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England

(2020) Shamez N. Ladhani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide

(2019) Alessandro Muzzi et al.   VACCINE

A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines

(2019) Jamie Findlow et al.   Human Vaccines & Immunotherapeutics

Introduction of a second MenB vaccine into Europe – needs and opportunities for public health

(2019) Jamie Findlow et al.   Expert Review of Vaccines

Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis

(2019) Bing Wang et al.   VACCINE

Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch

(2019) G. Deceuninck et al.   VACCINE

Distribution of Neisseria meningitidis serogroup b (NmB) vaccine antigens in meningococcal disease causing isolates in the United States during 2009–2014, prior to NmB vaccine licensure

(2019) How-Yi Chang et al.   JOURNAL OF INFECTION

Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis

(2019) Ali Purmohamad et al.   MICROBIAL PATHOGENESIS

Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269

(2019) Maria Stella et al.   Human Vaccines & Immunotherapeutics

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

(2018) Lisa K. McNeil et al.   mBio

Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents – Results from a randomized, controlled, observer-blind phase II study

(2018) Jo Anne Welsch et al.   VACCINE

Meningococcal B vaccine (4CMenB): the journey from research to real world experience

(2018) Rino Rappuoli et al.   Expert Review of Vaccines

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

(2018) Reinaldo Acevedo et al.   Expert Review of Vaccines

Emerging experience with meningococcal serogroup B protein vaccines

(2017) Daniela Toneatto et al.   Expert Review of Vaccines

Complement: A primer for the coming therapeutic revolution

(2017) Scott R. Barnum   PHARMACOLOGY & THERAPEUTICS

Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States

(2017) Gowrisankar Rajam et al.   mSphere

The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines

(2016) Stephen I. Pelton   JOURNAL OF ADOLESCENT HEALTH

The Genetics ofNeisseriaSpecies

(2014) Ella Rotman et al.   Annual Review of Genetics

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

(2013) Giacomo Frosi et al.   VACCINE

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

(2011) Xin Wang et al.   VACCINE